A to Z: Drugs in Highlight: K is for KALYDECO®
News, A to Z Feature
13/02/2025
This series continues to explore the fascinating world of pharmaceuticals. KALYDECO® (from Vertex Pharmaceutical Limited) uses ivacaftor for treating cystic fibrosis in people with certain mutations in the gene for a protein called cystic fibrosis transmembrane conductance regulator (CFTR).
Read more
Protect Your Global Brand: Essential Trade Mark Services
News
11/02/2025
In today's globalised marketplace, a strong brand is more than just a name or logo. It's a powerful asset, a beacon of recognition for customers, and a crucial element in building a thriving business. Yet many businesses, regardless of size, overlook the importance of safeguarding this valuable intangible property.
Read more
A to Z: Drugs in Highlight: J is for JANUVIA®
News, A to Z Feature
06/02/2025
This series explores the fascinating world of pharmaceuticals. Learn about IMBRUVICA®, a medication used to treat blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia. Discover how it works by targeting a specific enzyme, its global market approval, and the patent protection surrounding this innovative treatment.
Read more
UPC finds infringement by way of equivalence for the first time
Industry news, News
03/02/2025
The Unified Patent Court (UPC) has made a significant ruling, finding that Arkyne Technologies infringed a patent on microbial fuel cells (MFCs) even though their device did not literally match the patent's claims. The court applied the "doctrine of equivalents," a legal principle that allows for infringement when a product or process achieves the same result in a functionally equivalent way. This decision has important implications for both patent holders and potential infringers.
Read more
A to Z: Drugs in Highlight: I is for IMBRUVICA®
News, A to Z Feature
30/01/2025
This series explores the fascinating world of pharmaceuticals. Learn about IMBRUVICA®, a medication used to treat blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia. Discover how it works by targeting a specific enzyme, its global market approval, and the patent protection surrounding this innovative treatment.
Read more
Unlocking Faster Cancer Treatments: The Power of Project Orbis
Industry news, News
27/01/2025
Project Orbis, an FDA-led global initiative, envisions a world where cutting-edge cancer treatments reach patients swiftly. By collaborating with regulatory agencies worldwide (including the UK), Project Orbis streamlines the review process for oncology drugs, accelerating access to life-saving therapies. This article delves into the mechanics of Project Orbis within the UK and its transformative influence on cancer care
Read more